Welcome to Capital Essence

Sign up for a FREE MEMBERSHIP to read tons of free content. Take a 30-DAY Trial Offer to access premium research and trading strategy. Check out our Investment Blog for the latest trading/investment ideas. If you want to go beyond the latest numbers, our Market Outlook will tell you why the market does what it does and what it means for the next day’s trading.

Trading Strategy – VanEck Vectors Semiconductor ETF

  One of the noteworthy developments in recent days has been the move in semis.  The group was under selling pressure Thursday after Taiwan Semiconductor Manufacturing (TSMC) said it expects second-quarter revenue to range between $7.8 billion and $7.9 billion, well below a Wall Street consensus estimate of $8.8 billion.  Shares of Apple fell 2.8 …[read more]

SPDRs Report

Good Morning. This is Capital Essence’s U.S. Market ETFs Trading Map – SPDRs Sector Report for April 20, 2018. Editor’s note: this column was originally published on Capital Essence’s CEM News. It’s being republished as a bonus for the loyal readers. For more information about subscribing to CEM News, please click here. Below, daily, weekly …[read more]

Trading Strategy – PowerShares DB Base Metals Fund

  One of the noteworthy developments in recent days has been the move in commodities. Raw materials have rallied sharply this week on escalating global political tensions and fears of Russian supply disruptions after the recent U.S. sanctions.  The PowerShares DB Base Metals Fund (DBB) soared nearly 10 percent MTD, outperformed the S&P by a …[read more]

SPDRs Report

Good Morning. This is Capital Essence’s U.S. Market ETFs Trading Map – SPDRs Sector Report for April 19, 2018. Editor’s note: this column was originally published on Capital Essence’s CEM News. It’s being republished as a bonus for the loyal readers. For more information about subscribing to CEM News, please click here. Below, daily, weekly …[read more]

Trading Strategy – SPDR S&P Biotech ETF

  One of the noteworthy developments in recent days has been the move in biotech. After an impressive ran that saw the SPDR S&P Biotech ETF (XBI) surged more than 43 percent in 2017, the ETF extended the winning streak, up more than 7 percent YTD, outperformed the S&P by a wide margin.  Now the …[read more]

Archives

Translate this Page